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Purpose: ABO incompatible (ABOi) kidney transplantation (KT) has been increasing to compensate for the shortage of organ 
donors. However, detailed comparative analyses of ABOi KT with ABO compatible (ABOc) KT are still rare. Methods: This 
retrospective study compared 12 consecutive ABOi KTs to 50 ABOc KTs that employed the same maintenance im-
munosuppressive agents during the same period. Comparisons of patient survival, graft survival, graft function, and compli-
cations were made until post-transplant day 90. Results: Baseline characteristics of the two groups were similar except for the 
positivity of panel reactive antibody (12% in the ABOc group vs. 42% in the ABOi group; P = 0.029). There were no significant 
differences in patient survival, graft survival, post-operative renal function, incidence of acute rejection, infections, or medi-
cal and surgical complications. However, bleeding complications were more common in the ABOi group (25%) than versus 
the ABOc group (6%) (P = 0.08). The preoperative and total hospital stay of the ABOi patients was significantly longer than 
the ABOc patients (P = 0.001). Conclusion: ABOi KT is a viable and safe option for patients whose only donor is blood in-
compatible, despite the longer preoperative hospital stay for preparation.
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INTRODUCTION
The ideal treatment for end-stage renal disease (ESRD) is 
kidney transplantation (KT). However, the considerable 
shortage of donor organs and the increasing number of pa-
tients with ESRD on KT waiting lists often have resulted in 
unacceptably long waiting times for an appropriate organ 
allograft. Despite only a slight increase in the number of 
KTs performed in Korea in the past decade, the number of 
ESRD patients requiring renal replacement therapy has 
markedly increased from 23,900 in 1998 to 56,396 in 2009. 
At the end of 2008, there were more than 7,000 patients 
awaiting KT and the median wait time was 1,660 days [1,2].
The increasing demand for KT requires an expanded 
pool of potential kidney donors. One option is anti-blood 
group-incompatible (ABOi) living donors. ABO incom-ABO-incompatible KT
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patibility had, until recently, been regarded as an absolute 
contraindication to living donor transplantation because 
of the high risk of hyperacute rejection [3]. Alexandre et al. 
[4,5] reported the first planned successful ABOi KT using 
plasmapheresis (PP) and splenectomy, although the over-
all short- and long-term rates of graft survival were poor. 
However, in the modern era of immunosuppression, the 
use of the protocol that includes PP plus rituximab has led 
to encouraging results [6-8]. Recently, ABOi KT was also 
started in Korea; the data is scanty [9].
To be generally used in a donor organ program, ABOi 
KT must not have a negative impact on graft survival, pa-
tient survival, graft function, and complications compared 
with ABOc KT. However, a little comparative data is 
available. To address this important shortfall, the present 
study compared 12 consecutive ABOi KTs to 50 ABOc KTs 
that employed the same maintenance immunosuppress-
ive agents during the same period. Comparisons of patient 
survival, graft survival, graft function, and complications 
were made until post-transplant 90th day.
METHODS
This comparative retrospective and cross-sectional 
study was approved by the Seoul St. Mary’s Hospital 
Institutional Review Board.
Patients
From May 2009 to March 2010, 12 patients were pre-
pared for ABOi living donor KTs and none were excluded 
due to magnitude of their ABO antibody (Ab) titer. As a 
control group, 50 ABOc living donor KTs performed dur-
ing the same period were selected on the basis of the initial 
maintenance immunosuppressive therapy (tacrolimus, 
mycophenolate mofetil, and corticosteroids; see below). 
Another 10 ABOc living donor KTs that were done during 
the same period had been maintained on other im-
munosuppressive agents, and so were excluded. 
Immunosuppression 
All kidney recipients of both ABOc and ABOi grafts re-
ceived basiliximab (20 mg on days 0 and 4; Simulect, 
Novatis Pharmaceuticals Co., Basel, Switzerland) as anti-
body induction. Maintenance immunosuppression con-
sisted of tacrolimus (Tacrobell, Chong Kun Dang Pharma-
ceuticals Co., Seoul, Korea; Prograf, Astellas Pharma Inc., 
Toyama, Japan), corticosteroid, and either mycophenolate 
mofetil (Cellcept, Hoffmann-La Roche Inc., Nutley, NJ, 
USA) or mycophenolate sodium (Myfortic, Novatis Phar-
maceuticals Co.). 
In the ABOc group, tacrolimus and corticosteroid was 
started on pretransplant day 2. A trough level of tacrolimus 
was maintained at 8 to 12 ng/mL in the first month and 6 to 
8 ng/mL thereafter. Methylprednisolone was administered 
at a dose of 125 mg/day, 250 mg/day, 500 mg/day, 240 
mg/day, and 180 mg/day on pretransplant day 2, 1, oper-
ation day, posttransplant day 1 and 2, respectively. 
Prednisolone (30 mg/day) was prescribed beginning at 
posttransplant day 3 and was rapidly tapered to a dose of 
10 mg/day by 1 month post-transplantation. Mycopheno-
late mofetil (1,500 mg/day twice daily or 1,000 mg/day 
twice daily if body weight ＜50 kg) or mycophenolate so-
dium (1,080 mg/day twice daily or 720 mg/day twice daily 
if body weight ＜50 kg) was begun on operation day. The 
recipients receiving ABOc allograft with positive comple-
ment dependent cytotoxicity test were additionally pre-
pared with single dose of rituximab (375 mg/m
2; Roche 
Pharma AG, Renach, Switzerland) and plasma exchange 
(PE) followed by 100 mg/kg of intravenous immunoglo-
bulin (IVIG) 7 days before planned operation. 
In the ABOi group, a single dose of rituximab (100 to 375 
mg/m
2) was administered 1 month before the anticipated 
transplantation. On seven days before the scheduled oper-
ation, a triple oral immunosuppression regimen consist-
ing of tacrolimus, mycophenolate mofetil or mycopheno-
late sodium, and prednisolone (20 mg/day) were started. 
The target trough level of tacrolimus and the dosage of 
mycophenolate mofetil or mycophenolate sodium were 
same as used for the ABOc recipients. Twenty milligrams 
of prednisolone was changed to methylprednisolone on 
preoperative day 2. The dosage of methylprednisolone 
was 125 mg/day, 250 mg/day, 1,000 mg/day, 500 mg/day, 
240 mg/day, and 180 mg/day on day preoperative day 2, 1, 
operation day, postoperative day 1, 2, and 3, respectively. 
Prednisolone (30 mg/day) was prescribed beginning on Jeong Kye Hwang, et al.
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Table 1. Recipient and donor characteristics and recipient comorbidity
ABO-compatible (n = 50) ABO-incompatible (n = 12) P-value
Recipient sex (male)               27 (54)                 7 (58) 0.786
Recipient age (yr) 41.6 ± 12.1 (16-73)   45.6 ± 9.7 (28-61) 0.290
Recipient body mass index (kg/m
2)   23.4 ± 3.9 (16.8-33.1)   23.1 ± 3.7 (19.3-30.4) 0.811
Donor sex (male)               22 (44)                 4 (33.3) 0.746
Donor age (yr) 43.5 ± 11.9 (20-62)   37.8 ± 9.8 (18-49) 0.134
Type of donor (related)               31 (62)                 6 (50) 0.625
Cause of end stage renal disease 0.227
Chronic glomerulonephritis               16 (32)                 3 (25)
Diabetes mellitus                 7 (14)                 3 (25)
Hypertension               16 (32)                 2 (16.7)
Chronic pyelonephritis                 1 (2)                 0 (0)
Polycystic kidney disease                 0 (0)                 1 (8.3)
Lupus nephritis                 4 (8)                 0 (0)
Unknown                 6 (12)                 3 (25)
Type of renal RRT 0.631
Hemodialysis               32 (64)                 9 (75)
Peritoneal dialysis               10 (20)                 1 (8.3)
None                 8 (16)                 2 (16.7)
Duration of RRT (mo)             44.1 ± 84.2             31.9 ± 38.4 0.627
Diabetic mellitus before KT                 9 (18)                 4 (33.3) 0.686
Hypertension before KT               39 (78)                 8 (66.7) 0.461
Hx of erythropoietin Tx               26 (52)                 9 (75) 0.202
Hx of pregnancy               15 (30)                 3 (25) 1.000
Hx of blood transfusion               20 (40)                 6 (50) 0.528
First KT                46 (92)                 9 (75) 0.125
HLA mismatch               3.4 ± 1.8               3.5 ± 1.4 0.830
Cross match positive
CDC                 2                 1 0.482
FCMX                 3                 1 1.000
PRA (≥20%)                 6 (12)                 5 (41.7) 0.029
DS-HLA Ab                 5 (10)                 1 (8.3) 1.000
Cytomegalovirus
Ig G               50 (100)               12 (100) 1.000
Ig M                 0 (0)                 0 (0) 1.000
Epstein-Barr virus
Ig G               48 (96)               12 (100) 1.000
Ig M                 4 (8)                 1 (8.3) 1.000
Nephron mass index (g/kg)     3.0 ± 0.8 (1.7-5.3)     2.9 ± 0.8 (1.9-4.8) 0.668
Total ischemic time (min)   47.1 ± 9.7 (31-79) 56.3 ± 13.0 (43-85) 0.008
Values are presented as number (%) or mean ± SD (range).
RRT, renal replacement therapy; KT, kidney transplantation; Hx, history; Tx, treatment; HLA, human leukocyte antigen; CDC, complement 
dependent cytotoxicity assay; FCMX, flow-cytometric cross-match test; PRA, panel reactive antibody; Ab, antibody.
postoperative day 4 and was rapidly tapered to a dose of 
10 mg/day by 1 month post-transplantation. 
All ABOi recipients received cytomegalovirus (CMV) 
prophylaxis (valganciclovir) for 3 months post-oper-
atively, regardless of CMV serostatus. All ABOc and ABOi 
recipients received Pneumocystis jiroveci prophylaxis 
(trimethoprim, 80 mg/day; sulfamethoxazole, 400 mg/day) 
for 6 months and fungal prophylaxis (fluconazole, 100 
mg/day) for 1 month.
Plasma exchange and intravenous immunoglobulin
All patients receiving ABOi KT were treated before trans-
plantation with an every other day PE (one plasma volume 
exchanged with 5% albumin) followed by 100 mg/kg of 
IVIG. The final preoperative PE and all post-operative PEs 
were performed with donor blood type fresh frozen ABO-incompatible KT
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Table 2. Patient characteristics of ABO-incompatible living donor kidney transplantation
Patient Age/Sex Donor Cause of ESRD
Dialysis duration
(mo)
HLA MM No. of KT
Blood type
D →  R
Initial higher 
ABO Ab titer
1 51/M Spouse CGN 6 6 1 B＋  →  O＋ 1,024
2 50/M Spouse DM 1 4 1 B＋  →  A＋ 32
3 47/M Spouse DM 50 6 1 A＋  →  O＋ 512
4 33/M Sister Unknown 18 3 1 B＋  →  A＋ 64
5 41/F Sister CGN 24 2 2 B＋  →  O＋ 128
6 53/F Daughter DM PET 3 1 AB＋  →  B＋ 128
7 47/F Son Unknown 1 2 1 B＋  →  A＋ 32
8 61/M Son HTN PET 3 1 B＋  →  O＋ 256
9 48/M Spouse PCKD 22 4 1 B＋  →  O＋＞ 1,024
10 28/F NR CGN 24 2 2 AB＋  →  A＋ 512
11 34/F Spouse Unknown 1 4 1 A＋  →  O＋ 256
12 54/M Brother HTN 6 3 2 A＋  →  O＋ 256
ESRD, end-stage renal disease; HLA MM, human leukocyte antigen mismatch; KT, kidney transplantation; D, donor; R, recipient; Ab, 
antibody; NR, non-related; CGN, chronic glomerulonephritis; DM, diabetes mellitus; HTN, hypertension; PCKD, polycystic kidney disease;
PET, pre-emptive transplantation .
plasma. The number of pre-transplant PEs was determined 
by the baseline of ABO Ab titer [6]. The acceptant criterion 
of anti-blood type Ab titer was ≤1:32 at the time of 
transplantation. Postoperative PE was performed only if 
there was a rise in ABO Ab with concomitant impairment of 
the graft function except for the first case. ABO Ab titers 
were determined using an established tube test [10].
Demographic and clinical data
To compare the baseline characteristics of two groups, 
the following data were collected: donor and recipient age 
at KT; previous history of KT; gender; cause of ESRD; type 
and duration of renal replacement therapy; pre-operative 
comorbidity (e.g., diabetes mellitus, hypertension); pre-
vious blood transfusion, pregnancy, or erythropoietin 
treatment; number of human leukocyte antigen (HLA) 
mismatches; presence of panel reactive antibody (PRA) 
and donor-specific HLA antibody; serologic status of CMV 
and Epstein-Barr virus; nephron mass; and total ischemic 
time. To evaluate and compare the outcome; data on pa-
tient and graft survival; incidence of biopsy proven acute 
rejection, renal function, infections, medical, and surgical 
complications; duration of hospital stay; and re-admission 
episodes were collected until post-transplant 90th day. 
Renal function
Graft function was assessed by recording serum crea-
tinine (SCr), estimated glomerular filtration rate (eGFR) 
using the modification of diet in renal disease (MDRD) 
formula, urine protein-to-creatinine ratio (UPCR) on 
post-transplantation day 7, 30, 60, and 90. Recipients who 
experienced allograft loss were excluded from the analysis 
after the point of graft loss.
Statistics
All data are presented as mean ± standard deviation. 
Comparisons between the two groups were performed us-
ing Student's t test. P ＜  0.05 was considered statistically 
significant.
RESULTS
Preoperative demographic and clinical factors
Donor and recipient baseline characteristics were sim-
ilar in both groups, except for sensitization (PRA ≥  20% in 
41.7% of ABOi recipients and 12% of ABOc recipients) and 
cold ischemic time (56.3 ± 13 minutes in ABOi recipients 
vs. 47.1 ± 9.7 minutes in ABOc recipients; P = 0.008, re-
spectively) (Table 1).
Patient characteristics, anti-blood-type antibody 
titer in ABOi recipients 
Results are summarized in Tables 2, 3. Twelve adult Jeong Kye Hwang, et al.
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Table 3. Higher anti-A/B antibody titer and antibody removal of ABO-incompatible living donor kidney transplantation
Patient Rituzimab Pre-KT PE
Higher ABO Ab titer
Post-KT PE
KT day 1 wk 1 mo 2 mo 3 mo
1 5 0 0 98848 83
2 7 5 0 64244 80
35 0 091 61 63 23 2 3 2 0
4 1 7 5 64222 20
5 5 0 0 58424 20
6 100 6 8 16 64 64 128 4
7 2 0 0 34022 20
8 2 0 0 78 1 688 40
9 160 12 32 16 GF GF GF 3
1 0 6 0 0 98244 40
11 150 7 32 8 16 16 16 0
12 600 7 64 8 16 16 16 1
KT, kidney transplantation; PE, plasma exchange; Ab, antibody; GF, graft failure.
Table 4. Patient and graft survival and post-operative renal function in living donor kidney transplant recipients
ABO-compatible (n = 50) ABO-incompatible (n = 12) P-value
Patient and graft survival
Patient survival                     50 (100)                     12 (100) 1.000
　Graft loss                       1 (2)                       1 (8.3) 0.482
　Delayed graft function                       1 (2)                       0 (0) 1.000
Graft function
Serum creatinine (mg/dL)
1 wk after KT       1.11 ± 0.58 (0.53-4.03)       0.93 ± 0.40 (0.48-2.05) 0.293
1 mo after KT       1.28 ± 0.44 (0.68-3.22)       1.19 ± 0.31 (0.67-1.57) 0.492
2 mo after KT       1.26 ± 0.33 (0.71-2.29)       1.19 ± 0.24 (0.76-1.49) 0.420
3 mo after KT       1.26 ± 0.33 (0.84-2.54)       1.16 ± 0.25 (0.66-1.49) 0.281
eGFR by MDRD (mL/min/1.73 m
2)
1 wk after KT       79.5 ± 26.3 (12.1-140.4)       94.2 ± 31.4 (36.6-147.3) 0.071
1 mo after KT       64.0 ± 19.6 (15.6-111.9)       66.5 ± 19.0 (39.8-100.3) 0.597
2 mo after KT       62.7 ± 15.8 (23.2-93.5)       63.7 ± 11.1 (51.0-86.7) 0.720
3 mo after KT       61.5 ± 14.3 (20.6-99.8)       66.5 ± 15.4 (50.5-102.0) 0.260
UPCR (mg/g)
1 wk after KT      781 ± 1,350 (100-7,441)         461 ± 478 (31-1,637) 0.365
1 mo after KT      558 ± 1,095 (24-3,687)         201 ± 234 (3-1,468) 0.140
2 mo after KT         159 ± 221 (11-1345)           109 ± 61 (31-243) 0.451
3 mo after KT         112 ± 127 (1-712)           110 ± 83 (29-269) 0.667
Acute rejection episode (%)       8 in 7 patients (16)         3 in 3 patients (25) 0.515
Hospital stay (day)
Total         24.4 ± 6.2 (17-46)        39.0 ± 13.1 (22-72) 0.003
Pre-operative           6.2 ± 2.3 (2-14)          16.3 ± 4.6 (8-23) 0.003
Post-operative         18.2 ± 5.6 (13-38)        22.7 ± 10.9 (14-49) 0.198
Values are presented as number (%) or mean ± SD (range).
KT, kidney transplantation; eGFR by MDRD, estimated glomerular filtration rates by modification of diet in renal disease; UPCR, urine 
protein-to-creatinine ratio.
ABOi patients (mean age, 45.6 ± 9.7 years; range, 28 to 61 
years; seven males and five females) were successfully 
transplanted at our institution since May 2009. There were 
B incompatibility in eight cases and A incompatibility in 
four cases. Elevated pre-treatment ABO Ab titers ranged 
from 32 times to more than 1,024 times. Median higher ABO-incompatible KT
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Table 5. Complications in living donor kidney transplant recipients
ABO-compatible (n = 50) ABO-incompatible (n = 12) P-value
Infectious complications                        34 (68)                          6 (50) 0.242
Viral infection                        24 (48)                          6 (50) 0.691
CMV infection                        11 (22)                          3 (25) 1.000
CMV disease                          2 (4)                          0 (0) 1.000
BKV infection                          5 (10)                          2 (16.7) 0.612
Other viral infection                          6 (12)                          1 (8.3) 1.000
Bacterial infection                          9 (18)                          0 (0) 0.185
Candidia infection                          1 (2)                          0 (0) 1.000
Surgical complications                          9 (18)                          3 (25) 0.686
Bleeding                          3 (6)                          3 (25) 0.081
Deep vein thrombosis                          3 (6)                          0 (0) 1.000
Ureteral stricture                          2 (4)                          0 (0) 1.000
Bowel perforation                          1 (2)                          0 (0) 1.000
Medical complications                        11 (22)                          6 (50) 0.051
Post transplant diabetes mellitus (%)           6 in 41 patients (14.6)             3 in 10 patients (30) 0.406
Steroid induced complications                          1 (2)                          1 (8.3) 0.352
Leukopenia                          1 (2)                          2 (16.7) 0.093
Cardiac complications                          2 (4)                          0 (0) 1.000
Seizure                          1 (2)                          0 (0) 1.000
Total complications                        54 (108)                        15 (125)
Values are presented as number (%).
ABO Ab titer were 256 (32 to 1,024), 8 (4 to 64), 8 (0 to 16), 
4 (2 to 64), 8 (2 to 64), and 8 (2 to 128) on pre-treatment day 
0, 7, 30, 60, and 90, respectively. When compared with the 
pre-treatment level, the reduction of Ab titer was observed 
at all time points except patient number 6. The mean num-
ber of pre-operative PEs needed to achieve a target ABO 
Ab titer of 1:32 was 7.2 ± 2.3 (3 to 12) and the mean number 
of post-operative PE in four patients was 2.8 ± 1.3 (1 to 44).
Patient and graft survival and renal allograft function
Overall patient survival was 100% in both groups for 90 
days post-operatively. Graft survival was 98% in the ABOc 
group and 92% in the ABOi group on post-transplant 90th 
day. In the ABOc group, one graft loss and one delayed 
graft function occurred. The graft loss was due to an acute 
cellular rejection on post-operative day 21 and the failed 
graft was removed. One graft was removed in the ABOi 
group on post-operative day 22 because of uncontrolled 
bleeding from biopsy site (Table 4). The graft was 
removed. SCr, eGFR by MDRD, and UPCR obtained on 
postoperative day 7, 30, 60, and 90 revealed no significant 
difference between the two groups. The ABOi patients dis-
played slightly better (but statistically insignificant) renal 
allograft functions on those days (Table 4). 
Acute rejection
All rejections were confirmed upon biopsy. The in-
cidence of acute rejection was 16% and 25% in the ABOc 
and ABOi group, respectively (P = 0.515). In the ABOc 
group, seven patients experienced eight episodes of acute 
rejection, one acute antibody mediated rejection (AAMR) 
and seven acute cellular rejection. In the ABOi group, 
three suffered acute rejection, one AAMR and two acute 
cellular rejections (Table 4). 
Complications 
All infectious, medical, and surgical complications are 
listed in Table 5. No difference was apparent between the 
two groups. 
There were no serious and lethal infectious compli-
cations. No significant differences were evident in the in-
cidence of viral, bacterial, and fungal infection between 
the two groups (P = 0.691, 0.185, and 1.000, respectively). 
CMV infection occurred in 11 patients (22%) of the ABOc 
group and in three patients (25%) of the ABOi group. Two 
other patients (4%) in the ABOc group experienced CMV Jeong Kye Hwang, et al.
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disease in a renal allograft (n = 1) and the duodenum (n = 
1). All cases of CMV infection and disease were success-
fully treated by ganciclovir treatment. Seven patients had 
positive polyoma BK virus replication in the blood but 
none developed polyoma virus associated nephropathy. 
Nine cases of bacterial infection developed only in the 
ABOc group; seven cases were urinary tract infections that 
responded well to antibiotic treatment.
Overall, there was a trend toward increased medical 
complications in the ABOi group compared to the ABOc 
group (50% vs. 22%, respectively; P = 0.051). Leukopenia 
and post-transplant diabetes mellitus developed more fre-
quently in the ABOi group compared with the ABOc group 
(leucopenia: 16.7% vs. 2%, respectively; P = 0.093) (diabe-
tes: 30% vs. 14.6%, respectively; P = 0.406). The overall in-
cidence of surgical complications was similar between the 
two groups (P = 0.686). Major bleeding complications re-
quiring operation or transfusion with more than two units 
of packed red cells were more frequent in the ABOi group 
(25%) than in the ABOc group (18%), but this difference 
was not statistically significant (P = 0.08). Three cases of 
deep vein thrombosis occurred in the ABOc group.
Hospitalization
The pre-transplant hospital stay was significantly lon-
ger in the ABOi group (16.3 ± 4.6 days) compared with the 
ABOc group (6.2 ± 2.3 days) (P = 0.003). The post-trans-
plant hospital stay was similar between the two groups (P 
= 0.198). 
DISCUSSION
The goal of ABOi KT is to increase the number of KTs 
and to avoid or shorten the time on dialysis. For ABOi do-
nors to become widely used in KT, the allograft function 
and potential risks must be equal to those after ABOc KT. 
Yet, comparative data is lacking. Presently, ABOi KT recip-
ients (n = 12) were compared for 3 months after KT with 50 
ABOc KT patients whose regimen had included the same 
basic immunosuppression. This short-term study demon-
strated that the outcomes of ABOi KT using PE plus ritux-
imab is equivalent to that from an ABOc KT in terms of pa-
tient survival, graft survival, graft function, post-oper-
ative complications, and total hospital stay. 
Unfortunately, in up to one-third of cases, kidney dona-
tion is refused due to blood group incompatibility. The use 
of living donor KT would boost the available transplants 
by 10 to 20% [6,11,12]. The number of living donor KTs at 
our hospital has increased by 12% (from 60 to 72) since the 
start of the ABOi KT program in May 2009. ABOi KT per-
formed in a donor exchange program will likely increase 
the number of living donor KTs. 
Before this goal can be achieved, protocols to overcome 
the ABOi barrier will be necessary for successful ABOi 
KT. As an initial approach, PE with splenectomy was 
used, but more widespread implementation was frus-
trated by the high rates of infection and rejection [5,13]. 
However, in the modern era of immunosuppression, pro-
tocols using PP plus rituximab have led to encouraging 
results [6-8]. 
In this study, patient and graft survival of the ABOi 
group for 3 months after KT was good and did not differ 
from that of the ABOc group. Even patients with very high 
initial ABO Ab titers (patients 1 and 9, ≥1,024) were suc-
cessfully transplanted for 90 days. Therefore, consistent 
with previous studies, a high initial ABO Ab titer should 
not be an exclusion criterion for ABOi KT [14,15]. The tar-
get ABO Ab titers in our institution is ≤1:16 at the time of 
transplantation until patient 8, after which the inclusion 
criteria for ABOi KT was expanded to those with titers of 
1:32. The target ABO Ab titers at which a KT can safely be 
performed are different between each center, due to differ-
ences in titration methods, type of PP, and dosage and tim-
ing of rituximab use. Some centers aim at a titer level ≤4, 
while others target a titer level of ≤32 [8,15-17]. Due to use 
of different detection method, it is difficult to compare the 
published data on the outcome of ABOi KT. Exact meas-
urement of ABO Ab titers is critical for successful ABOi KT 
[18]. However, no standard method for quantitative deter-
mination has yet been established. In most institutions 
performing ABOi KT, the tube test is used to determine the 
ABO Ab titers. However, significant inter-institutional 
variability in the measurement of ABO Ab can occur [15]. 
When different techniques were compared, only flow cy-
tometry yielded a very consistent outcome in repeated ABO-incompatible KT
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measurements, indicating its adoption as an international 
standard to determine ABOi [19-21].
It is well-known that the risk for AAMR after an ABOi KT 
is highest in the first 2 weeks after the operation, and can cor-
relate with the post-operative ABO Ab titer [22,23]. A very 
high incidence of graft loss occurs in patients who experi-
enced AMR during this critical period [24]. This has prompt-
ed many centers to employ a protocol with routine fixed 
scheduled post-operative PP during the first 2 weeks after 
transplantation [25,26]. Although a routine postoperative 
PP is effective to prevent acute cellular rejection, it can in-
crease cost, prolong hospitalization, and increase the risk of 
PP-related complications. Recently, many centers have 
adopted a policy where post-operative PP is done only if 
there is an increase in the anti-blood type Ab titer to a certain 
level [15,27] or a rise in ABO Ab titer with concomitant im-
pairment of graft functions [7,8]. We also performed se-
lective postoperative PP if there was a rise in anti-blood type 
Ab titer with concomitant impairment of renal functions, ex-
cept for the first case. Elimination of routine postoperative 
PE did not result in an increased incidence of AAMR in our 
series. Postoperative PP was performed on only three (27%) 
of the 11 ABOi recipients. Among them, only one case of 
AAMR was confirmed, and was successfully treated with 
four sessions of PE and steroid pulse therapy. 
Table 5 shows the type and incidence of complications 
after living donor KT. Between the two groups, there were 
no statistical differences in overall complications. Since 
Tydén et al. [25] reported on ABOi KT without splenec-
tomy using rituximab in 2003, most transplant centers 
have adopted rituximab instead of splenectomy as a B-cell 
ablation therapy in ABOi KT. Increased risk of infectious 
complications have been reported after the use of ritux-
imab for other indications [28,29], but have not been 
well-studied in solid organ transplantation. One of our 
major concerns was that the routine administration of rit-
uximab would lead to an increased rate of infectious 
complications. But, we did not experience an increased 
risk of infectious complications after ABOi KT, despite rit-
uximab induction. The incidence of CMV infection was 
the same as the ABOc group (25% vs. 22%, respectively), 
and CMV disease did not occur in the ABOi group. The in-
cidence of CMV infection was relatively lower than anoth-
er report [30]. We administered valganciclovir prophylac-
tically in the ABOi group and this is likely the reason why 
there was a relatively lower incidence and severity of CMV 
infection compared with other studies and the ABOc 
group. The rates of positive BKV replication in the blood 
that did not develop to overt BKV nephropathy were also 
the same in both groups. Although statistically insignif-
icant, bleeding complications occurred more frequently in 
the ABOi group, whereas deep vein thrombosis devel-
oped only in the ABOc group. These two findings suggest 
that the ABOi group has an upward tendency to defect on 
coagulation. A possible explanation for the coagulopathy 
in our series is the method of PP. Theoretically, PE removes 
much more coagulation factors than double filtration PP 
or immunoadsorption [22]. Medical complications tended 
to occur more often in the ABOi group compared to the 
ABOc group (50% vs. 22%, respectively; P = 0.051). More 
post-transplant diabetes mellitus and leukopenia devel-
oped in the ABOi group. The higher applied dose of corti-
costeroid, longer pre-operative use of oral immuno-
suppressives, and rituximab may have played a role. As 
expected, pre-operative hospital stay was significantly 
longer in ABOi recipients, primarily because of the 
pre-operative PE (P = 0.003). However, post-operative hos-
pitalization was nearly same between the two groups.  
We conclude that the short-term results of the ABOi KT 
using this regimen are equivalent to that of the ABOc KT in 
patient survival, graft survival, and graft function, with-
out any serious complications. 
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